Synaptogenix Profit Margin

The latest profit margin for SNPX is -34329396.01% as of June 2026. That compares with -425190.11% in the prior-year period — down 7973.9% year over year. That is below the Healthcare sector average of 10.58%. Investors often review this figure alongside Synaptogenix's historical trend and sector peers before judging valuation or financial health.

Over the past year, SNPX's profit margin moved from -425190.11% to -34329396.01% — a 7973.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Synaptogenix's valuation or profitability profile.

Against Healthcare companies, SNPX currently prints -34329396.01% for profit margin, while the sector average sits near 10.58%. That is roughly 324460156.8% below the sector mean. Large gaps often invite a closer look at Synaptogenix's growth, margins, and balance sheet.

Profit Margin shows how effectively Synaptogenix converts resources into returns. At -34329396.01%, SNPX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -425190.11% in the prior-year period — down 7973.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SNPX's profit margin (-34329396.01%), review year-over-year change from -425190.11%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.